VS-6063 for Ovarian Cancer

Phase-Based Progress Estimates
University of California San Diego, San Diego, CAOvarian CancerVS-6063 - Drug
All Sexes
What conditions do you have?

Study Summary

This trial will test the safety and efficacy of the combination of VS-6063, carboplatin, and paclitaxel in patients with ovarian cancer.

Eligible Conditions
  • Ovarian Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: 4 years

4 years
Objective response rate (ORR)
To assess the safety and tolerability of VS-6063 plus paclitaxel and carboplatin chemotherapy (Measured Via Adverse Events)
To assess the toxicity and adverse event profile of VS-6063 plus paclitaxel and carboplatin chemotherapy (Measured Via Adverse Events)
To describe health-related quality-of-life (QoL) outcomes of patients receiving VS-6063 plus paclitaxel and carboplatin chemotherapy. (Measured Via Questionnaire)
overall survival (OS)
progression free survival (PFS)

Trial Safety

Trial Design

1 Treatment Group

Defactinib (VS-6063) +Carboplatin/Paclitaxel
1 of 1

Experimental Treatment

90 Total Participants · 1 Treatment Group

Primary Treatment: VS-6063 · No Placebo Group · Phase 1 & 2

Defactinib (VS-6063) +Carboplatin/PaclitaxelExperimental Group · 3 Interventions: Carboplatin, Paclitaxel, VS-6063 · Intervention Types: Drug, Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 4 years

Who is running the clinical trial?

Nine Girls AskUNKNOWN
Michael McHaleLead Sponsor
Verastem, Inc.Industry Sponsor
33 Previous Clinical Trials
1,956 Total Patients Enrolled
2 Trials studying Ovarian Cancer
122 Patients Enrolled for Ovarian Cancer

Eligibility Criteria

Age 18+ · All Participants · 9 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You do not currently have an infection that requires treatment with antibiotics, except for a simple urinary tract infection.
Your bone marrow, kidneys, liver, and nervous system need to be functioning well. You must have fully recovered from any recent surgeries, radiation, or chemotherapy. Any side effects from previous chemotherapy must be mild.

Frequently Asked Questions

What clinical indications is VS-6063 commonly utilized for?

"Beyond its effectiveness in treating melanoma, VS-6063 has been shown to reduce the growth of neoplasm metastasis, lymphomas, and various types of sarcoma." - Anonymous Online Contributor

Unverified Answer

Is access to this research project currently available for participants?

"Indeed, current information on clinicaltrials.gov specifies that this research is actively recruiting participants. The study was first published on February 6th 2018 and was last modified January 23rd 2020; the investigators are hoping to recruit 90 people at a single location." - Anonymous Online Contributor

Unverified Answer

What further investigations have been conducted regarding the effects of VS-6063?

"In total, 1182 studies are currently underway studying the therapeutic potential of VS-6063. Of those active investigations, 332 have progressed to Phase 3 and span 68069 locations with a majority located in Shanghai." - Anonymous Online Contributor

Unverified Answer

How extensive is the scope of this experimental program?

"Correct. According to clinicaltrials.gov, this medical trial is actively seeking participants from a single location and 90 people in total. The study was first posted on February 6th 2018 with the most recent update occurring January 23rd 2020." - Anonymous Online Contributor

Unverified Answer

What are the essential goals of this trial?

"The objectives of this 4 year trial are to gauge the safety and tolerability of VS-6063 plus paclitaxel and carboplatin chemotherapy (as evaluated through adverse events), observe changes in health related quality-of-life among patients receiving treatment, document any toxicities that may arise from therapy, and record overall survival rates as per RECIST 1.1 standards." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.